

## lenacapavir tablet (SUNLENCA)

### Diagnoses Considered for Coverage:

- Multi-drug resistant HIV-1 infection

### Coverage Criteria:

#### For multidrug-resistant HIV-1 infection:

- Being used for initiation, followed by subcutaneous maintenance treatment, **and**
- Prescribed by or in consultation with an Infectious Disease or HIV specialist, **and**
- Patient's HIV-1 isolate has documented resistance to at least one (1) antiretroviral medication from three (3) separate drug classes of antiretroviral medications, **and**
- Confirmation that Sunlenca will be taken in combination with an optimized background antiretroviral regimen which contains at least one other partially or fully active antiretroviral medication, **and**
- Dose does not exceed FDA label maximum.

### Coverage Duration: one time for initiation dose

### References:

1. Sunlenca® (lenacapavir) [Prescribing information.] Foster City, CA: Gilead Sciences, Inc.; 12/2022.

Effective Date: 3/1/2023